Concordance of HER2 in primary tumor and leptomeningeal metastases: Now what?

Breast Cancer Research and Treatment

Volumn 123, Issue 1, 2010, Pages 129-131

  Lin, Nancy U ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ESTROGEN RECEPTOR; LAPATINIB; METHOTREXATE; PROGESTERONE RECEPTOR; THIOTEPA; TRASTUZUMAB;

BREAST CANCER; CANCER CELL; CANCER RELAPSE; CANCER RESISTANCE; CEREBROSPINAL FLUID EXAMINATION; CLINICAL FEATURE; CYTOLOGY; DISEASE ACTIVITY; DRUG SAFETY; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MENINGEAL METASTASIS; METASTASIS POTENTIAL; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; BREAST TUMOR; CARCINOMATOUS MENINGITIS; CEREBROSPINAL FLUID; FEMALE; GENETICS; PROTO ONCOGENE; SECONDARY;

BREAST NEOPLASMS; CEREBROSPINAL FLUID; FEMALE; GENES, ERBB-2; HUMANS; MENINGEAL CARCINOMATOSIS; RECEPTOR, ERBB-2;

EID: 77955775627     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0720-7     Document Type: Note

References (27)

1. WR Wasserstrom JP Glass JB Posner 1982 Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients Cancer 49 4 759 772 10.1002/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0. CO;2-7 1:STN:280:DyaL387hsV2ltw%3D%3D 6895713
2. Fisher R, DeAngelis LM (2010) Leptomeningeal metastasis. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Disease of the breast, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1000-1007
3. IB Fuchs M Loebbecke H Buhler,, et al. 2002 HER2 in brain metastases: issues of concordance, survival, and treatment J Clin Oncol 20 19 4130 4133 10.1200/JCO.2002.04.016 12351617
4. Johnson ML, Nehhozina T, Conlin AK, et al (2008) Clinical and pathologic correlates in breast cancer (BC) brain metastasis (BM): tissue microarray (TMA) studies. J Clin Oncol 26(May 20 suppl):abstract 1039
5. D Gancberg A Di Leo F Cardoso,, et al. 2002 Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites Ann Oncol 13 7 1036 1043 10.1093/annonc/mdf252 1:STN:280:DC%2BD38vitFWgtQ%3D%3D 12176781
6. MacFarlane R, Speers C, Masoudi H, Chia S (2008) Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series. J Clin Oncol 26(May 20 suppl):Abstract 1000
7. C Liedtke K Broglio S Moulder,, et al. 2009 Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer Ann Oncol 20 12 1953 1958 10.1093/annonc/mdp263 1:STN:280: DC%2BD1MjntFOrtQ%3D%3D 19596702
8. JM Wu MJ Fackler MK Halushka,, et al. 2008 Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases Clin Cancer Res 14 7 1938 1946 10.1158/1078-0432.CCR-07-4082 1:CAS:528:DC%2BD1cXkt1aktbg%3D 18381931 (Pubitemid 351551102)
9. BH Nam SY Kim HS Han,, et al. 2008 Breast cancer subtypes and survival in patients with brain metastases Breast Cancer Res 10 1 R20 10.1186/bcr1870 18307763
10. JC Bendell SM Domchek HJ Burstein,, et al. 2003 Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma Cancer 97 12 2972 2977 10.1002/cncr.11436 12784331 (Pubitemid 36676250)
11. Brufsky AM, Mayer M, Rugo HS, et al (2008) RegistHER: patient characteristics and time course of central nervous system metastases in patients with HER2-positive metastatic breast cancer. In: ASCO Breast cancer symposium, 2008, p Abstract 89, Washington, D.C., 2008
12. K Altundag ML Bondy NQ Mirza,, et al. 2007 Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis Cancer 110 12 2640 2647 10.1002/cncr.23088 1:CAS:528:DC%2BD1cXitVOitA%3D%3D 17960791 (Pubitemid 350250332)
13. J Lamovec M Bracko 1991 Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study J Surg Oncol 48 1 28 33 10.1002/jso.2930480106 1:STN:280:DyaK3Mzms12htA%3D%3D 1653879
14. FC Bidard MN Guilhaume H Gauthier PH Cottu V Dieras JY Pierga 2009 Meningeal carcinomatosis in HER2-overexpressing breast cancers J Neurooncol 93 2 287 288 10.1007/s11060-008-9768-1 1:STN:280:DC%2BD1MzkslOktQ%3D%3D 19139826
15. Gauthier H, Guilhaume M-N, Bidard FC, et al (2009) Meningeal carcinomatosis in patients with breast cancer: clinical features and prognostic factors in 91 patients from a single institution. Cancer Res 69(Suppl):abstract 1090
16. NU Lin E Claus J Sohl AR Razzak A Arnaout EP Winer 2008 Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases Cancer 113 10 2638 2645 10.1002/cncr.23930 18833576
17. HJ Stemmler M Schmitt N Harbeck,, et al. 2006 Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer Oncol Rep 15 5 1373 1377 1:CAS:528:DC%2BD28XksFKiurY%3D 16596213
18. HJ Stemmler K Mengele M Schmitt,, et al. 2008 Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report Anti-cancer drugs 19 8 832 836 10.1097/CAD.0b013e32830b58b0 1:CAS:528:DC%2BD1cXpsFKqu7o%3D 18690096
19. C Platini J Long S Walter 2006 Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab Lancet Oncol 7 9 778 780 10.1016/S1470-2045(06)70864-6 16945774 (Pubitemid 44283672)
20. J Siderov 2006 Care with intrathecal trastuzumab Lancet Oncol 7 11 888 10.1016/S1470-2045(06)70917-2 17081914 (Pubitemid 44636942)
21. YL Tham L Hinckley BS Teh R Elledge 2006 Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report Clin Breast Cancer 7 2 164 166 10.3816/CBC.2006.n.028 16800978
22. T Shigekawa H Takeuchi M Misumi,, et al. 2009 Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report Breast Cancer 16 1 88 92 10.1007/s12282-008-0056-x 18478315
23. NU Lin V Dieras D Paul,, et al. 2009 Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer Clin Cancer Res 15 4 1452 1459 10.1158/1078-0432.CCR-08-1080 1:CAS:528:DC%2BD1MXitVOktLo%3D 19228746
24. Boccardo F, Kaufman B, Baselga J, et al (2008) Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastses (BM) from HER2 + breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU). J Clin Oncol 26:abstract 1094
25. JA Engelman K Zejnullahu T Mitsudomi,, et al. 2007 MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 5827 1039 1043 10.1126/science.1141478 1:CAS:528: DC%2BD2sXltlOjt7g%3D 17463250 (Pubitemid 46799492)
26. RA Ghoussoub DA Dillon T D'Aquila EB Rimm ER Fearon DL Rimm 1998 Expression of c-met is a strong independent prognostic factor in breast carcinoma Cancer 82 8 1513 1520 10.1002/(SICI)1097-0142(19980415)82:8<1513:: AID-CNCR13>3.0.CO;2-7 1:STN:280:DyaK1c3htlWqsQ%3D%3D 9554529 (Pubitemid 28164998)
27. DL Shattuck JK Miller KL Carraway III C Sweeney 2008 Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells Cancer Res 68 5 1471 1477 10.1158/0008-5472.CAN-07-5962 1:CAS:528: DC%2BD1cXislagu70%3D 18316611 (Pubitemid 351346855)